论文部分内容阅读
目的:探讨下瘀血汤对进展期四氯化碳(CCl4)大鼠肝纤维化的干预作用。方法:采用50%CCl42ml/kg体重皮下注射,每周2次;第9周开始随机分为模型对照组、下瘀血汤组及小柴胡汤组(灌胃给药);用药的同时继续CCl4造模至12周末杀鼠取材。观测肝功能、肝组织病理学、肝组织羟脯氨酸(Hyp)含量变化。结果:8周末模型大鼠肝功能显著异常,肝组织Hyp含量显著增加,肝纤维化明显;12周末模型对照组天冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)、γ-L-谷氨酰转肽酶(GGT)、总胆红素(TBil)、Hyp进一步增高,且ALP、GGT、TBil显著高于8周模型对照组(P<0.05)。与12周模型对照组比较,下瘀血汤组丙氨酸氨基转移酶(ALT)、AST、ALP、GGT、TBil、Hyp显著降低(P<0.05或P<0.01)。结论:下瘀血汤能显著抑制造模因素持续刺激条件下进展期肝纤维化的发展,疗效优于小柴胡汤,方证相关有其病理学基础。
Objective: To investigate the effect of Xiabi blood decoction on hepatic fibrosis in rats with advanced carbon tetrachloride (CCl4). Methods: 50% CCl42ml/kg body weight was injected subcutaneously twice a week. From the 9th week, they were randomly divided into model control group, XiaQi blood decoction group and Xiaochaihu Decoction group (gastric administration); while continuing the treatment, CCl4 was continued. Modeling until 12 weekends to kill rodents. Liver function, liver histopathology, and changes in liver tissue hydroxyproline (Hyp) levels were observed. Results: At the end of 8 weeks, the liver function of the model rats was significantly abnormal, the liver tissue Hyp content increased significantly, and hepatic fibrosis was obvious. At the end of the 12th week, the model control group was aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ- L-glutamyl transpeptidase (GGT), total bilirubin (TBil), and Hyp were further increased, and ALP, GGT, and TBil were significantly higher than those in the 8-week model control group (P<0.05). Compared with the 12-week model control group, the alanine aminotransferase (ALT), AST, ALP, GGT, TBil, and Hyp in the Xiaxue Xuetang group were significantly decreased (P<0.05 or P<0.01). Conclusion: Xiayi blood decoction can significantly inhibit the development of hepatic fibrosis under the condition of persistent stimulating factors, and the curative effect is better than that of Xiaochaihu decoction. The prescription-related syndrome has its pathological basis.